机译:Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Breast Oncology Peking University Cancer Hospital&Institute Beijing 100142 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
AcornMed Biotechnology Co. Ltd. Beijing 101102 China;
Section of Clinical Biochemistry University Hospital of Verona Verona 37100 Italy;
Department of Breast and Medical Oncology National Cancer Center Hospital East Kashiwa 277-8577 Japan;
Clinical Oncology General Organization for Teaching Hospitals Cairo 11435 Egypt;
Department of Radiation Oncology Hospital Sírio-Libanês Sao Paulo 01308-050 Brazil;
Multidisciplinary Breast Center Fondazione Policlinico Universitario A.Gemelli IRCCS UniversitàCattolica del Sacro Cuore Rome 00176 Italy;
Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Unit of Medical Oncology Fondazione Policlinico Universitario A.Gemelli IRCCS Roma 00176 Italy;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Pathology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 China;